RU2018124983A - Пептидная композиция - Google Patents

Пептидная композиция Download PDF

Info

Publication number
RU2018124983A
RU2018124983A RU2018124983A RU2018124983A RU2018124983A RU 2018124983 A RU2018124983 A RU 2018124983A RU 2018124983 A RU2018124983 A RU 2018124983A RU 2018124983 A RU2018124983 A RU 2018124983A RU 2018124983 A RU2018124983 A RU 2018124983A
Authority
RU
Russia
Prior art keywords
peptide composition
peptide
composition according
paragraphs
self
Prior art date
Application number
RU2018124983A
Other languages
English (en)
Other versions
RU2018124983A3 (ru
RU2740185C2 (ru
Inventor
Юя СУГАНУМА
Тацуя ОДЗИО
Хиденори ЙОКОИ
Original Assignee
Меникон Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Меникон Ко., Лтд. filed Critical Меникон Ко., Лтд.
Publication of RU2018124983A3 publication Critical patent/RU2018124983A3/ru
Publication of RU2018124983A publication Critical patent/RU2018124983A/ru
Application granted granted Critical
Publication of RU2740185C2 publication Critical patent/RU2740185C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Claims (12)

1. Пептидная композиция, включающая
самособирающийся пептид;
буферный агент, имеющий pKa, составляющую 3,5 или более, но менее 7,5, и содержащий один или более атомов азота; и
воду,
при этом пептидная композиция имеет рН от 4,5 до 6,6.
2. Пептидная композиция по п. 1, в которой суммарный заряд аминокислотных остатков, содержащихся в самособирающемся пептиде, составляет между более 0 и +3 или менее в пептидной композиции.
3. Пептидная композиция по п. 1 или 2, в которой С-конец самособирающегося пептида включает амидную группу.
4. Пептидная композиция по любому из пп. 1-3, в которой аминокислота на С-конце самособирающегося пептида включает основную аминокислоту.
5. Пептидная композиция по любому из пп. 1-4, в которой буферный агент включает гистидин, нитрат тиамина, пиридин, бис-трис, этилендиамин и/или N-метилморфолин.
6. Пептидная композиция по любому из пп. 1-5, в которой концентрация буферного агента составляет от 1 мМ до 100 мМ.
7. Пептидная композиция по любому из пп. 1-6, которая имеет коэффициент пропускания видимого света 70% или более.
8. Способ получения пептидной композиции по любому из пп. 1-7, включающий перемешивание самособирающегося пептида, буферного агента, имеющего pKa, составляющую 3,5 или более, но менее 7,5, и содержащего один или более атомов азота, и воды.
RU2018124983A 2015-12-10 2015-12-10 Пептидная композиция RU2740185C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2015/084638 WO2017098627A1 (ja) 2015-12-10 2015-12-10 ペプチド組成物

Publications (3)

Publication Number Publication Date
RU2018124983A3 RU2018124983A3 (ru) 2020-01-13
RU2018124983A true RU2018124983A (ru) 2020-01-13
RU2740185C2 RU2740185C2 (ru) 2021-01-12

Family

ID=58745684

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018124983A RU2740185C2 (ru) 2015-12-10 2015-12-10 Пептидная композиция

Country Status (10)

Country Link
US (1) US10702606B2 (ru)
EP (1) EP3388089B1 (ru)
JP (1) JP6134081B1 (ru)
KR (1) KR102429287B1 (ru)
CN (1) CN108367094B (ru)
AU (1) AU2015416589B2 (ru)
HK (1) HK1257745A1 (ru)
NZ (1) NZ743237A (ru)
RU (1) RU2740185C2 (ru)
WO (1) WO2017098627A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788001C2 (ru) * 2017-12-20 2023-01-16 Магле Кемосвед Холдинг Аб Водная композиция для обнаружения просачивания физиологических жидкостей

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501552B1 (en) 2017-12-20 2020-02-26 Magle Chemoswed Holding AB A body fluid leakage detection aqueous composition
EP3741388A4 (en) * 2018-01-19 2021-11-17 Menicon Co., Ltd. IMMUNOGENIC COMPOSITION
EP4112089A4 (en) * 2020-02-28 2024-03-13 Menicon Co Ltd PREVENTIVE MATERIAL FOR DIGESTIVE FLUID LEAKAGE AND ORGAN PROTECTION MATERIAL AGAINST DIGESTIVE FLUID

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819078A1 (de) 1988-06-04 1989-12-07 Hoechst Ag Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
ATE227583T1 (de) 1991-12-20 2002-11-15 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
WO1995001368A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Improved synthesis of cyclic peptides
RU2067000C1 (ru) * 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
EP1843776A4 (en) 2004-07-06 2011-05-11 3D Matrix Inc PURIFIED AMPHILIC PEPTIDE COMPOSITIONS AND ITS USE
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
US8299032B2 (en) * 2005-06-27 2012-10-30 Menicon Co., Ltd. Self-assembling peptide and gel produced from the same
CN100402646C (zh) * 2005-07-07 2008-07-16 徐放 一种生产重组人骨形态发生蛋白的方法
JP2007217376A (ja) * 2006-02-17 2007-08-30 Nagoya Institute Of Technology 自己組織化ペプチド組成物
CN101448853A (zh) * 2006-03-17 2009-06-03 比奥根艾迪克Ma公司 稳定的多肽组合物
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2089047B1 (en) 2006-12-11 2012-11-14 3D Matrix, Inc. Compositions and methods for cardiac tissue protection and regeneration
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US20100021224A1 (en) * 2008-07-22 2010-01-28 Love John C Cutting station for an image forming apparatus
EP2757108B1 (en) 2009-03-09 2016-08-31 Menicon Co., Ltd. Self-assembling peptide and peptide gel with high strength
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102206250B (zh) * 2010-03-29 2017-03-15 翔升科技股份有限公司 低血球溶解性的抗微生物肽、药物组合物及其用途
JP2012082180A (ja) * 2010-10-14 2012-04-26 Nagoya Univ 骨再生用自己組織化ペプチドハイドロゲル
US8835387B2 (en) * 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
SG11201503370WA (en) * 2012-11-06 2015-05-28 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
JP2014214153A (ja) 2013-04-30 2014-11-17 ニプロ株式会社 水溶液製剤およびその製造方法
JP2015144767A (ja) 2014-02-04 2015-08-13 学校法人愛知学院 骨形成促進材
JP2016020323A (ja) * 2014-07-16 2016-02-04 国立大学法人名古屋大学 神経再生足場材料用組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788001C2 (ru) * 2017-12-20 2023-01-16 Магле Кемосвед Холдинг Аб Водная композиция для обнаружения просачивания физиологических жидкостей

Also Published As

Publication number Publication date
US20180344861A1 (en) 2018-12-06
RU2018124983A3 (ru) 2020-01-13
CN108367094A (zh) 2018-08-03
KR20180085014A (ko) 2018-07-25
EP3388089A4 (en) 2019-07-10
NZ743237A (en) 2024-02-23
CN108367094B (zh) 2021-09-14
US10702606B2 (en) 2020-07-07
AU2015416589B2 (en) 2021-04-01
EP3388089A1 (en) 2018-10-17
RU2740185C2 (ru) 2021-01-12
HK1257745A1 (zh) 2019-10-25
AU2015416589A1 (en) 2018-06-28
JP6134081B1 (ja) 2017-05-24
EP3388089B1 (en) 2022-05-18
KR102429287B1 (ko) 2022-08-05
JPWO2017098627A1 (ja) 2017-12-07
WO2017098627A1 (ja) 2017-06-15

Similar Documents

Publication Publication Date Title
AR067701A1 (es) Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
HRP20210342T1 (hr) Pripravci glikopeptida
EP3636656A4 (en) PROCESS FOR SYNTHESIS OF A PEPTIDE CONTAINING AN N-SUBSTITUTED AMINO ACID
JP2017533218A5 (ru)
WO2014149387A8 (en) Solid phase peptide synthesis processes and associated systems
WO2015173325A8 (en) Improved immunoglobulin variable domains
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
RU2018124983A (ru) Пептидная композиция
HRP20120903T4 (hr) Tekuća formulacija koja sadrži visoku koncentraciju protutijela
EA201690623A1 (ru) Простациклиновые соединения, композиции и способы их использования
SG10201811186XA (en) Purification of proteins
EA200970880A1 (ru) Стабильные композиции на основе антител
JP2017518072A5 (ru)
AR070587A1 (es) Composiciones efervescentes de limpieza y metodos de aplicacion
RU2019116756A (ru) Жидкая фармацевтическая композиция
MX2018007581A (es) Dominios variables de inmunoglobulina mejorados.
RU2017101667A (ru) Фармацевтические композиции
WO2015198240A3 (en) Compositions and methods for long acting proteins
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
EA201591678A1 (ru) Антиперспирантные композиции
EA201291170A1 (ru) Специфические системы с низким содержанием поверхностно-активных веществ мягкого действия, с высоким содержанием смягчающих средств, которые сохраняют пенообразование и фазовую устойчивость
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.